PROMPT:

Write a concise summary of the following:


by the total number of individuals enrolled in the plan divided by the total number of individuals enrolled in a prescription drug plan or an MAPD plan.  This section defines the terms "extended-monopoly drug" and "long-monopoly drug" for purposes of the drug pricing provisions in this bill. An extended-monopoly drug is a selected drug for which at least 12, but fewer than 16, years have elapsed since its approval or licensure. A long-monopoly drug is a selected drug for which at least 16 years have elapsed since its approval or licensure. Vaccines are excluded from both definitions.  The average manufacturer price for a selected drug is determined by the average of the non-Federal manufacturer prices for the drug for the four calendar quarters of the year involved. For a qualifying single source drug with an initial price applicability year of 2029 or 2030, the maximum fair price negotiated under this section for such drug for such initial price applicability year may not be less than 66 percent of the average non-Federal average manufacturer price for such drug for 2021. The Secretary shall consider the following manufacturer-specific data when determining the offers and counteroffers for the selected drug: research and development costs of the manufacturer for the drug, historical sales volume of the drug, and other factors as determined by the Secretary.  The bill requires the Secretary of Health and Human Services to select a drug for negotiation in order to secure the best possible price for the drug, taking into account the following factors: the manufacturer's research and development costs, the current unit costs of production and distribution, prior Federal financial support for novel therapeutic discovery and development, data on pending and approved patent applications and exclusivities, market data and revenue and sales volume data. In addition, the Secretary must consider evidence about alternative treatments, including the extent to which the drug


CONCISE SUMMARY:

==========

RESPONSE:

This bill defines the terms "extended-monopoly drug" and "long-monopoly drug" for purposes of the drug pricing provisions in this bill. An extended-monopoly drug is a selected drug for which at least 12, but fewer than 16, years have elapsed since its approval or licensure. A long-monopoly drug is a selected drug for which at least 16 years have elapsed since its approval or licensure. Vaccines are excluded from both definitions. The average manufacturer price for a selected drug is determined by the average of the non-Federal manufacturer prices for the drug for the four calendar quarters of the year involved. For a qualifying single source drug with an initial price applicability year of 2029 or 2030, the maximum fair price negotiated under this section for such drug for such initial price applicability year may not be less than 66 percent of the average non-Federal average manufacturer price for such drug for 2021. The Secretary of Health and Human Services must select a drug for negotiation in order to secure the best possible price for the drug, taking into account the following factors: the manufacturer's research and development costs, the current unit costs of production and distribution, prior Federal financial support for novel therapeutic discovery and development, data on pending and approved patent applications and exclusivities, market data and revenue and sales volume data. In addition, the Secretary must consider evidence about alternative treatments, including the extent to which the drug